Oct. 27th, 2015
HCC surveillance in an era of biomarkers
Doctor Robert G. Gish, a world renowned hepatologist, speaks about the importance of including biomarkers for HCC risk assessment in liver cancer surveillance programs and proposes his current liver surveillance algorithm as a model. To view the presentation:
Clinical Diagnostic and
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in the United States and Canada.
Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. Our products are the result of over 90 years of dedication to the field of laboratory science and research development. Our superior research reagents are easy to use and have a robust history of utilization in academia.